This 8.6% Yielding TSX Powerhouse Looks Ridiculously Undervalued

Stop what you’re doing and consider undervalued stocks, especially this one.

| More on:
concept of real estate evaluation

Source: Getty Images

It’s not easy to find a stock that pays out a hefty dividend, shows consistent performance, and trades at what looks like a bargain. But every so often, one appears to tick all the boxes. MCAN Mortgage (TSX:MKP) is exactly that kind of stock right now. With a yield around 8.6%, a steady track record of dividend payments, and an undervalued share price, this TSX-listed powerhouse deserves a closer look.

About the stock

MCAN is a mortgage investment corporation. That means it earns money by investing in residential and commercial mortgages, as well as other real estate-based assets. It operates much like a bank, but without the same kind of overhead or exposure to traditional banking risks. Because it focuses primarily on generating income from its mortgage portfolio, it’s able to pass much of that income onto shareholders through dividends. And right now, those dividends are looking especially juicy.

As of writing, MCAN’s annualized dividend yield sits at 8.6%. That’s well above what you’d get from most blue-chip dividend stocks or even a high-interest savings account. The quarterly dividend currently pays $0.41 per share, and those payments have not only been steady, but growing. In 2023, MCAN raised its dividend from $0.38 to $0.41 per share and has kept it there since.

And it’s not just the yield that makes this company attractive. The earnings continue to support the dividend. In its most recent annual report, MCAN announced net income of $77.6 million for 2024. Earnings per share (EPS) came in at $2.06. While this was a modest drop from $2.14 in 2023, it was still more than enough to comfortably cover the annual dividend of $1.64. The payout ratio, which sits around 85%, remains well within sustainable levels for a company in this line of business.

Value on income

The stock is also trading at what appears to be a discount. Shares are hovering around $19 as of writing. That gives it a price-to-earnings ratio (P/E) of 9. For context, the average P/E ratio for companies in the diversified financials sector in Canada is closer to 12 or 13. MCAN is priced as though there are risks around the corner, but so far, it has continued to deliver. It has a strong return on equity of 13.4%, a solid indicator that it is generating value for shareholders.

What makes this especially interesting is that MCAN’s business thrives in the kind of environment we’re in now. Interest rates have remained higher for longer than many expected. While that’s been tough on borrowers, it has boosted yields on new mortgage investments. MCAN has been able to redeploy capital into higher-yielding opportunities as older loans mature. This shift has helped offset some of the softness seen in other parts of the real estate market.

Another positive for MCAN is its conservative management approach. It maintains a diverse and well-collateralized mortgage portfolio. The company is focused heavily on urban markets in Canada, with a tilt toward single-family residential loans. It also limits exposure to high-risk development lending. That helps shield it from some of the volatility seen in the broader real estate market, particularly in commercial segments.

Foolish takeaway

All told, MCAN Mortgage checks a lot of boxes. High yield? Check. Steady earnings? Check. Reasonable valuation? Check. With interest rates staying higher for longer, it’s well-positioned to keep delivering for investors who are looking for income today and value for tomorrow. This is one stock that looks ridiculously undervalued, and one that income-focused investors may want to scoop up before the market catches on.

Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Dividend Stocks

Concept of multiple streams of income
Dividend Stocks

Passive Income: How Much Do You Need to Invest to Make $400 Per Month?

This fund's fixed $0.10-per-share monthly payout makes passive-income math easy.

Read more »

voice-recognition-talking-to-a-smartphone
Dividend Stocks

How to Turn Losing TSX Telecom Stock Picks Into Tax Savings

Telecom stocks could be a good tax-loss harvesting candidate for year-end.

Read more »

Business success of growth metaverse finance and investment profit graph concept or development analysis progress chart on financial market achievement strategy background with increase hand diagram
Dividend Stocks

2 Dividend Growth Stocks Look Like Standout Buys as the Market Keeps Surging

Enbridge (TSX:ENB) stock and another standout name to watch closely in the new year.

Read more »

a person watches stock market trades
Dividend Stocks

For Passive Income Investing, 3 Canadian Stocks to Buy Right Now

Don't look now, but these three Canadian dividend stocks look poised for some big upside, particularly as interest rates appear…

Read more »

Dividend Stocks

Got $7,000? Where to Invest Your TFSA Contribution in 2026

Putting $7,000 to work in your 2026 TFSA? Consider BMO, Granite REIT, and VXC for steady income, diversification, and long-term…

Read more »

Young adult concentrates on laptop screen
Dividend Stocks

A Beginner’s Guide to Building a Passive Income Portfolio

Are you a new investor looking to earn safe dividends? Here are some tips for a beginner investor who wants…

Read more »

container trucks and cargo planes are part of global logistics system
Dividend Stocks

Before the Clock Strikes Midnight on 2025 – TSX Transportation & Logistics Stocks to Buy

Three TSX stocks are buying opportunities in Canada’s dynamic and rapidly evolving transportation and logistics sector.

Read more »

some REITs give investors exposure to commercial real estate
Dividend Stocks

The Ideal Canadian Stock for Dividends and Growth

Want dividends plus steady growth? Power Corporation offers a “quiet compounder” mix of cash flow today and patient compounding from…

Read more »